brincidofovir is one of several experimental drugs administered to a small number of patients to treat ebola virus disease during the 2014 outbreak. the who published a report on the ethics of using unregistered interventions to treat ebola, where they concluded that "in the particular context of the current ebola outbreak in west africa, it is ethically acceptable to offer unproven interventions that have shown promising results in the laboratory and in animal models but have not yet been evaluated for safety and efficacy in humans as potential treatment or prevention."